- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01767831
Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22904
- University of Virginia Center for Diabetes Technology
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
For this pilot trial, recruitment will ONLY occur through UVa's IRB-HSR #14263 Recruitment Database.
Inclusion criteria for subject to enroll:
- T1DM (as defined by the American Diabetes Association criteria or judgment of a physician) for at least 2 years prior to the enrollment in the study
- Age 21-65.
- Use of an insulin pump to treat their diabetes for at least 6 months.
- Use of a CGM for at least a 6 week period in the past 2 years.
- Has the ability to use a computer that is capable of running the Dexcom Data Manager 3 (DM3) software daily.
- Has regular access to the Internet.
- Has an identified healthcare provider who can provide advice about diabetes care.
- Actively using a bolus calculator function with the current insulin pump with pre-defined parameters for glucose goal, carbohydrate ratio, and insulin sensitivity factor.
- Willingness to participate in the study for 11 weeks wearing a DexCom CGM for the duration of the study and perform daily journaling of BG, pump activity, meals, physical activity, stress level and menstrual cycle for 3 weeks during the study intervention period.
- Willingness to do extra fingersticks when CGM alarms at low or high end (<70 mg/dl or >300 mg/dl),
- Willingness to come to Center for Diabetes Technology on at least two occasions to obtain and return supplies.
- Willingness to avoid consumption of acetaminophen-containing products for the duration of the study.
- Demonstration of proper mental status and cognition for completion of the study.
- Has the ability to contact their own personal diabetes care team to have clinical questions answered about changes to diabetes treatment.
Exclusion Criteria:
- Individuals with cognitive impairment that prevents understanding either consent form or intervention content
- Active renal dialysis
- Psychiatric disorders that would interfere with study tasks (e.g., substance abuse)
- History of a systemic deep tissue infection with methicillin-resistant staph aureus or Candida albicans
- Known bleeding diathesis or dyscrasia
- Pregnant or intending to get pregnant during study
- Active enrollment in another clinical trial
- Medical requirement for acetaminophen-containing products during the study period for more than 1 week
- Medical condition that would make operating a CGM or insulin pump difficult (e.g. blindness, severe arthritis, extensive scar tissue at sites where devices are inserted)
- Individuals who do not have access to their diabetes care team to have clinical questions answered about changes in their diabetes treatment.
- Need for magnetic resonance imaging (MRI)/magnetic resonance angiogram (MRA)during the study
List any restrictions on use of other drugs or treatments:
The CGM must be removed prior to Magnetic Resonance Imaging and use of acetaminophen-containing medications while using the CGM sensor may affect the performance of the device. Therefore, MRI and products containing acetaminophen will be restricted. If either is required out of medical necessity, the DexCom® will be removed and participant will have the option of repeating the involved study week. If the medical condition requires use of acetaminophen for longer than 1 week, the participant will be dropped from the study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
---|---|
Group A: CGM monitoring (1) vs Intervention
Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention.
The 4 week intervention period will be followed by an additional CGM monitoring period (session 2).
For those in Group A, we compare the data collection in CGM monitoring session 1 to the data collection in the intervention period.
|
The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data.
Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system.
Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness.
Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
Andre navne:
|
Group B: CGM monitoring (2) vs Intervention
Participants will undergo a 1 week CGM monitoring period (session 1), followed by a 4 week intervention period using the iBOLUSED intervention.
The 4 week intervention period will be followed by an additional CGM monitoring period (session 2).
For those in Group B, we compare the data collection in CGM monitoring session 2 to the data collection in the intervention period.
|
The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data.
Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system.
Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness.
Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Accuracy of Feedback and Intervention Feasibility
Tidsramme: within 6 months of study conclusion
|
We will assess the ability of our intervention to provide accurate, useful data to participants that can improve quality of life and educate patients regarding glycemic outcome based on participant feedback collected in focus groups, the post-intervention psychobehavioral assessment, and based on an analysis of the accuracy of the feedback data presented to users based on the input (diary) data.
A comparison of input diary data metrics (glucose and insulin data) to output feedback (BG risk profiles, glycemic variability metrics) will allow us to quantify this accuracy.
Feasibility of the intervention will be assessed through analysis of pre- and post- assessments, and through feedback provided by subjects during the focus group sessions.
A statistician with a background in qualitative data analysis will analyze the psychobehavioral assessment and focus group data.
|
within 6 months of study conclusion
|
Ability of Behavioral Intervention to Improve Glycemic Outcome
Tidsramme: within 6 months of study conclusion
|
Measure the ability of the simulation-based feedback system intervention to assist in improving the nominal glucose profile based on a pre- and post-intervention assessment of the data. We hypothesize that, compared to the use of CGM alone, the educational system will result in: A2.1: Increased time within target range, defined as 70-140mg/dl overnight and 70-180mg/dl during the day; A2.2: Reduced risk for hypoglycemia, specifically reduction in nocturnal hypoglycemic episodes; A2.3: Reduced postprandial glucose variability and avoidance of hypoglycemia 3-4 hours after a meal; and A2.4: Acceptance of the system feedback by patients. |
within 6 months of study conclusion
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Psychobehavioral Data to Inform Closed Loop Control Aggressiveness
Tidsramme: within 1 year of study conclusion
|
Collection of psychobehavioral data on individuals' fear of hypo- and hyperglycemia, and connecting the influence of these factors on insulin therapy self-management can facilitate the individualization of controller aggressiveness in the development of a closed-loop system. We study the ability of the psychobehavioral data to facilitate the individualization of controller aggressiveness in the development of a closed-loop system. The data that is used for this analysis are collected in through the pre- and post-intervention psychobehavioral assessments. |
within 1 year of study conclusion
|
Relationships Between Physiology and Behavior Transferred to In Silico Environment
Tidsramme: within 2 years from study conclusion
|
Collection of relevant data to establish relationships between behavior and physiology will allow to iteratively transfer, in simulation, the influence of behavioral triggers through individual physiological parameters and metabolic mechanisms, to the final element of BG fluctuation. The collected diary data will be used to establish relationships, specifically stochastic models, between behavioral events, physiology, and self-treatment. The models are developed based on the collected data and will be incorporated into the simulation environment to capture realistically physiologic response to behavior and self-treatment strategies. |
within 2 years from study conclusion
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Linda Gonder-Fredrick, Ph.D., University of Virginia Center for Diabetes Technology
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 16226
- R01DK085623 (U.S. NIH-bevilling/kontrakt)
- DP3DK094331 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 1 diabetes mellitus
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Diabetes type 1 | Type 1 diabetes mellitus | Autoimmun diabetes | Diabetes mellitus, insulinafhængig | Juvenil-Debut Diabetes | Diabetes, autoimmun | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | Diabetes mellitus, skør | Diabetes Mellitus... og andre forholdForenede Stater
-
University of California, San FranciscoJuvenile Diabetes Research FoundationAfsluttetType 1 diabetes mellitus | Diabetes mellitus, type I | Insulinafhængig diabetes mellitus 1 | Diabetes mellitus, insulinafhængig, 1 | IDDMForenede Stater, Australien
-
Capillary Biomedical, Inc.AfsluttetDiabetes mellitus, type 1 | Type 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, insulinafhængig, 1Australien
-
Spiden AGDCB Research AGRekrutteringType 1 diabetes mellitus | Type 1 diabetes mellitus med hypoglykæmi | Type 1 diabetes mellitus med hyperglykæmiSchweiz
-
Capillary Biomedical, Inc.AfsluttetType 1 diabetes | Type 1 diabetes mellitus | Diabetes mellitus, type I | Diabetes mellitus, insulinafhængig, 1 | IDDMØstrig
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute...UkendtType 1 diabetes mellitus med hyperglykæmi | Type 1 diabetes mellitus med hypoglykæmiPolen
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)AfsluttetType 1 diabetes mellitus | T1DM | T1D | Nyopstået type 1-diabetes mellitusForenede Stater, Australien
-
National Institute of Diabetes and Digestive and...AfsluttetDiabetes mellitus type 1Forenede Stater
-
Stem Cells ArabiaAfsluttetGlukosemetabolismeforstyrrelser | Metaboliske sygdomme | Sygdomme i immunsystemet | Autoimmune sygdomme | Sygdomme i det endokrine system | Diabetes mellitus type 1Jordan
-
Shanghai Changzheng HospitalRekrutteringSkør type 1 diabetes mellitusKina